AVXL Share Price | Anavex Life Sciences Corp. Stock Analysis & Recommendation

Q: What does Anavex Life Sciences Corp. do?

Overview:Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics for neurodegenerative and neurodevelopmental diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: Not availableMost recent Net Profit: -11 Million (Quarterly Results - Mar 2025)Market-cap: USD 761.52 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.16Return on Equity: -47.26%Price to Book: 7.63Contact Details:Address: 51 W 52nd St Fl 7th, NEW YORK NY: 10019-6163Tel: 1 800 6893939Website: https://www.anavex.com

Q: Who are in the management team of Anavex Life Sciences Corp.?

As of March 2022, the management team of Anavex Life Sciences Corp. includes Dr. Christopher Missling, who serves as the President, Chief Executive Officer, Secretary, and Director. Additionally, the Board of Directors features several independent directors: Dr. Peter Donhauser, Mr. Elliot Favus, Mr. Athanasios Skarpelos, Dr. Steffen Thomas, and Dr. Claus van der Velden. In summary, as of March 2022, Anavex Life Sciences Corp. is led by Dr. Christopher Missling, with a Board that includes five independent directors.

Q: Is Anavex Life Sciences Corp. technically bullish or bearish?

As of 14 August 2025, the technical trend for Anavex Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the monthly MACD and KST are bullish. However, weekly indicators such as MACD, Bollinger Bands, and Dow Theory show mildly bearish signals. The stock has underperformed against the S&P 500 in the short term, with a -9.50% return over the past week compared to the S&P 500's 1.05%, but it has outperformed over the past year with a 57.64% return versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.68 M

Shareholding (Sep 2025)

FII

4.72%

Held by 69 FIIs

DII

77.93%

Held by 21 DIIs

Promoter

0.12%

How big is Anavex Life Sciences Corp.?

22-Jun-2025

As of Jun 18, Anavex Life Sciences Corp. has a market capitalization of 761.52 million and reported net sales of 0.00 million with a net profit of -47.14 million. Shareholder's Funds are 120.26 million and Total Assets are 135.57 million.

View full answer

What does Anavex Life Sciences Corp. do?

22-Jun-2025

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental diseases. It has a market cap of $761.52 million and reported a net loss of $11 million in its most recent quarter.

View full answer

Who are in the management team of Anavex Life Sciences Corp.?

22-Jun-2025

As of March 2022, Anavex Life Sciences Corp. is led by Dr. Christopher Missling as CEO, with a Board of Directors that includes five independent members: Dr. Peter Donhauser, Mr. Elliot Favus, Mr. Athanasios Skarpelos, Dr. Steffen Thomas, and Dr. Claus van der Velden.

View full answer

Is Anavex Life Sciences Corp. technically bullish or bearish?

20-Sep-2025

As of August 14, 2025, Anavex Life Sciences Corp. has a mildly bullish trend, with daily moving averages supporting this stance, despite weekly indicators showing mild bearishness, and while it underperformed the S&P 500 in the short term, it outperformed over the past year.

View full answer

Compare Anavex Life Sciences Corp. with Similar Stocks

Alpine Immune Sciences, Inc.Enliven Therapeutics, Inc.Vera Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 474 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-48.88%

Price to Book

4.99

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-44.59%

6 Months

-62.63%

1 Year

-52.82%

2 Years

-29.19%

3 Years

-63.1%

4 Years

-60.69%

5 Years

-66.91%

Anavex Life Sciences Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-30.20%

EBIT to Interest (avg)

-45.52

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.16

Sales to Capital Employed (avg)

Tax Ratio

3.92%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

42.22%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.08

EV to EBIT

-10.70

EV to EBITDA

-10.70

EV to Capital Employed

-36.86

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-47.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (17.22%)

Foreign Institutions

Held by 69 Foreign Institutions (4.72%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.20% vs -7.96% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.50",
          "val2": "-14.70",
          "chgp": "1.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-12.20",
          "chgp": "-8.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 9.47% vs 1.04% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.90",
          "val2": "-55.80",
          "chgp": "5.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.00",
          "val2": "-47.50",
          "chgp": "9.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.50

-14.70

1.36%

Interest

0.00

Exceptional Items

0.00

0.10

-100.00%

Consolidate Net Profit

-13.20

-12.20

-8.20%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8.20% vs -7.96% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'24

Sep'24

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-52.90

-55.80

5.20%

Interest

0.00

1.00

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-43.00

-47.50

9.47%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 9.47% vs 1.04% in Sep 2023

All Annual Results

Company CV

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

Pharmaceuticals & Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

Company Coordinates

Company Details

51 W 52nd St Fl 7th , NEW YORK NY : 10019-6163

Tel: 1 800 6893939

https://www.anavex.com

Registrar Details

Anavex Life Sciences Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Anavex Life Sciences Corp.?

Watch in Real-Time

What does Anavex Life Sciences Corp. do?

Who are in the management team of Anavex Life Sciences Corp.?

Is Anavex Life Sciences Corp. technically bullish or bearish?

Compare Anavex Life Sciences Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Sep'24

About Anavex Life Sciences Corp.

Company Coordinates